Development of cryptococcal immune reconstitution inflammatory syndrome 41 months after the initiation of antiretroviral therapy in an AIDS patient by unknown
Hashimoto et al. AIDS Res Ther  (2015) 12:33 
DOI 10.1186/s12981-015-0075-6
CASE REPORT
Development of cryptococcal immune 
reconstitution inflammatory syndrome 
41 months after the initiation of antiretroviral 
therapy in an AIDS patient
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Abstract 
Cryptococcal meningitis is one of the most lethal fungal infections in patients with acquired immune deficiency 
syndrome (AIDS). The incidence of and mortality from cryptococcal meningitis have markedly decreased since the 
introduction of combination antiretroviral therapy (cART). However, despite its benefits, the initiation of cART results 
in immune reconstitution inflammatory syndrome (IRIS) in some patients. Although IRIS is occasionally difficult to 
distinguish from relapse or treatment failure, the distinction is important because IRIS requires a different treatment. 
Here, we present the case of a patient with AIDS who developed symptoms of cryptococcal IRIS 41 months after start‑
ing cART. To the best of our knowledge, the time between cART initiation and the onset of cryptococcal IRIS in this 
patient is the longest that has been reported in the literature.
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Background
Cryptococcal meningitis is one of the most lethal fungal 
infections in patients with acquired immune deficiency 
syndrome (AIDS) [1]. As an opportunistic infection, it 
may develop in patients whose CD4 cell counts are less 
than 100  cells/μL. Before the introduction of combina-
tion antiretroviral therapy (cART), cryptococcal menin-
gitis developed in 6–10 % of AIDS patients [1]. However, 
since the introduction of cART, the incidence of and 
mortality from cryptococcal meningitis and other oppor-
tunistic infections have decreased markedly in AIDS 
patients [2].
Some patients experience immune reconstitution 
inflammatory syndrome (IRIS) after the initiation of 
cART. IRIS is thought to occur when cART causes 
immune system recovery and thereby elicits paradoxical 
inflammatory responses to either previously diagnosed 
and treated or subclinical infections [3].
IRIS has been described in association with multi-
ple opportunistic pathogens, such as Mycobacterium 
avium complex, Mycobacterium tuberculosis, Cryptococ-
cus neoformans, cytomegalovirus, and hepatitis viruses. 
Although IRIS was initially described in human immuno-
deficiency virus (HIV)-infected patients who had started 
cART, it is now known to occur in other settings as well, 
such as in organ transplantation, patients after cessation 
of tumor necrosis factor (TNF)-α inhibitors, and preg-
nancy [4–6]. Cryptococcal IRIS most frequently pre-
sents as recurrent meningitis; however, it may manifest 
as intracranial space-occupying lesions and non-central 
nervous system presentations (e.g., lymphadenitis, pneu-
monitis, and ophthalmologic complications) [7]. Previous 
studies have reported that cryptococcal IRIS develops 
in 8–45  % of HIV-infected patients with cryptococcosis 
who responded to cART, despite the use of antifungal 
therapy. The mortality rate among these patients ranges 
from 8 to 30 % [7–10].
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Generally, IRIS occurs within a median of 12  weeks 
after starting cART [11]. Similarly, most cases of cryp-
tococcal IRIS have been shown to develop within 
12  months after the initiation of cART, with median 
intervals ranging from 1 to 10 months [7]. However, IRIS 
can also occur outside of the usual range. For example, 
cryptococcal IRIS has been reported as early as 4  days 
and as late as 37 months after starting cART [7, 8, 12].
In the following section, we present the case of an 
AIDS patient who developed symptoms of cryptococcal 
IRIS 41  months after starting cART. To the best of our 
knowledge, the time between cART initiation and the 
onset of cryptococcal IRIS in this patient is the longest 
that has been reported in the literature.
Case presentation
In December 2009, a 59-year-old man developed Pneu-
mocystis jirovecii pneumonia (PCP) and was diagnosed 
as having HIV-1 infection. His CD4 T cell count was 
44 cells/μL and his HIV RNA load was 16,000 copies/mL 
at diagnosis. He also had chronic hepatitis B. Two weeks 
after completing the treatment for PCP using adjunc-
tive corticosteroids, he was admitted to our hospital 
again after presenting with a gradually worsening head-
ache and fever. On admission, he had no neck stiffness, 
photophobia, or focal neurological abnormality. A com-
puted tomography (CT) scan of the head did not show 
any pathological findings. A lumbar puncture revealed 
an opening pressure of 350  mm H2O, cell counts of 7/
µL (100 % lymphocytes), protein levels of 29 mg/dL, and 
glucose levels of 40  mg/dL. Yeasts were seen on a cer-
ebrospinal fluid (CSF) smear. Both the CSF and blood 
cultures subsequently became positive for C. neoformans 
with minimum inhibitory concentrations of 1.0  µg/mL 
for amphotericin B, 4.0  µg/mL for fluconazole (FLCZ), 
and 4.0 µg/mL for flucytosine (5-FC). The patient’s initial 
blood and CSF cryptococcal antigen titers were 1:16,384 
and 1:4096, respectively. A chest X-ray film showed no 
abnormalities; however, white perivascular infiltrates 
that were compatible with fungal retinitis/endophthal-
mitis were observed in both ocular fundi. The patient 
was therefore diagnosed with disseminated cryptococ-
cosis with meningitis, retinitis, and cryptococcemia. He 
was treated with amphotericin B lipid complex (L-AmB) 
200 mg/day and 5-FC 6000 mg/day (which was decreased 
to 4000  mg/day because of the adverse effect of pancy-
topenia) for 2  weeks, followed by L-AmB 200  mg/day 
and FLCZ 400  mg/day for another 2  weeks. The initial 
treatment was followed by maintenance therapy (FLCZ 
200 mg/day). Fungal clearance was observed in the CSF 
obtained 15 days after starting antifungal therapy. Initial 
and subsequent CSF findings are shown in Table 1.
In March 2010, 5 weeks after the initiation of antifungal 
therapy for cryptococcosis, cART with tenofovir/emtric-
itabine plus lopinavir/ritonavir (LPV/r) was started. In 
May 2010, raltegravir replaced LPV/r due to the hepato-
toxicity associated with LPV/r. The HIV RNA load in the 
blood became undetectable within 3 months after start-
ing cART. His CD4 T-cell count recovered gradually to 
about 200 cells/μL without recurrence of PCP or crypto-
coccosis. To provide maintenance therapy for cryptococ-
cal meningitis, FLCZ was continued alongside cART.
In mid-August 2013, after 41  months of cART, the 
patient had a mild headache accompanied by mild nau-
sea. Approximately 1  week later, he presented with a 
generalized tonic–clonic seizure featuring worsening 
paralysis of the right leg. He was still receiving cART 
and FLCZ maintenance therapy for cryptococcosis, with 
good adherence. His CD4 T-cell count was 193 cells/μL, 
and his HIV RNA load was undetectable upon admis-
sion. A CT scan of the head revealed low-density areas 
in the subcortical region and deep white matter with 
Table 1 Initial and subsequent cerebrospinal fluid findings
CSF cerebrospinal fluid, NT not tested
Feb 2010 (Day 1 
of therapy)
Feb 2010 (Day 8 
of therapy)
March 2010 (Day 15 
of therapy)
March 2010 (Day 43 
of therapy)
Sep 2013
Cell counts (/µL) 7 10 4 1 9
Rate of mononuclear  
cells (%)
100 100 NT NT 100
Protein (mg/dL) 29 33 31 29 82
Glucose (mg/dL) 40 49 41 45 58
CSF‑to‑serum glucose  
ratio
0.41 0.32 0.36 0.48 0.59
Fungal smear Positive Positive Positive Negative Negative
Fungal culture Positive Positive Negative Negative Negative
Cryptococcal antigen titer 1:4096 NT 1:2048 NT 1:4
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surrounding edema in the left frontal and right temporal 
lobes. A brain magnetic resonance imaging (MRI) scan 
(Fig.  1a) showed high signal intensity on T2-weighted 
images without obvious mass effect. Contrast-enhanced 
MRI showed enhancement along the brain surface 
and cerebral sulcus, but the parenchyma showed little 
enhancement. A lumbar puncture was performed and 
showed clear CSF (9 white blood cells/μL) as well as nor-
mal glucose and protein levels (Table 1). India ink stains 
and cultures of the CSF sample were negative. Blood and 
CSF cryptococcal antigen tests were both positive; how-
ever, titers had decreased to 1:64 and 1:4, respectively, 
in comparison with the titers that had been obtained 
in 2010 (Table 1). Because we did not perform blood or 
CSF cryptococcal antigen tests between March 2010 and 
August 2013, it could not be determined whether the 
blood and CSF cryptococcal antigen titers had ever fallen 
below 1:64 and 1:4, respectively. Polymerase chain reac-
tion tests of the CSF for herpes simplex virus, varicella 
zoster virus, Epstein-Barr virus, and JC virus were all 
negative. A diagnostic brain biopsy of the left frontal lobe 
was therefore performed. The pathological examination 
revealed inflammatory cells and many rounded fungi that 
were detected on periodic acid-Schiff and Grocott stains 
in the subarachnoid cavity and periarteriolar spaces 
(Fig.  2). These findings were compatible with crypto-
coccal meningoencephalitis with white matter edema. 
Cultures of the brain tissue specimen were negative for 
Cryptococcus species and other fungal and bacterial 
pathogens. Thus, the patient was diagnosed with crypto-
coccal meningoencephalitis (mainly involving the menin-
ges) associated with IRIS.
He was treated again with L-AmB 200  mg/day and 
5-FC 3000  mg/day in addition to corticosteroid adjunc-
tive therapy [prednisolone 50  mg (1  mg/kg) daily] for 
2 weeks. This was followed by maintenance therapy with 
FLCZ 300 mg/day (which was adjusted according to renal 
function). The prednisolone dose was gradually tapered 
over 6 months. Discontinuation of antiretroviral therapy 
was not necessary during the course of the disease. His 
headache and right leg weakness resolved quickly, and 
the follow-up brain MRI scan obtained 3 weeks after the 
start of therapy showed an overall improvement with a 
marked decrease in the size of the white matter lesions 
(Fig. 1b).
Discussion
Recently, it has been recognized that cryptococcal IRIS 
presents in two distinct modes. Accordingly, the Inter-
national Network for the Study of HIV-Associated IRIS 
(INSHI) proposed two clinical case definitions of cryp-
tococcal IRIS among HIV-infected individuals. The first, 
paradoxical cryptococcal IRIS, presents as a worsen-
ing or recurring disease of previously recognized and 
treated cryptococcosis in the same or new anatomical 
sites, despite microbiological evidence suggesting that 
antifungal treatment has been effective. The second, 
ART-associated cryptococcosis, is defined as new-onset 
Fig. 1 MRI scans of the brain on admission and 3 weeks after the initiation of therapy. An MRI scan on admission a showed high signal intensity on 
T2‑weighted images in the white matter of the left temporal and right frontal lobes. Obvious mass effects were not observed. Contrast enhance‑
ment was seen along the brain surface and cerebral sulci; however, little enhancement of the brain parenchyma was detected. A follow‑up brain 
MRI scan obtained 3 weeks after the initiation of antifungal and steroid therapy b showed overall improvement with a marked decrease in the size 
of the white matter lesions
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cryptococcosis that occurs or is unmasked after starting 
cART [7]. Although there is no universally accepted defi-
nition of IRIS, our patient met the criteria for paradoxical 
cryptococcal IRIS according to the INSHI definitions.
Although the timing of onset appears to be quite varia-
ble, cryptococcal IRIS usually develops within 12 months 
after initiating cART and almost all cases occur within 
3  years [8]. The INSHI cutoff for the development of 
cryptococcal IRIS symptoms is 12 months after the ini-
tiation of cART; however, the network acknowledges 
that later onset of cryptococcal IRIS can occasionally 
occur [7]. Our patient developed symptoms of crypto-
coccal IRIS 41  months after starting cART, which is an 
extremely late onset.
In terms of its clinical presentation, cryptococcal men-
ingitis associated with IRIS may sometimes be difficult to 
distinguish from relapses [13]; however, negative culture 
results and good FLCZ compliance (as secondary proph-
ylaxis) may help to distinguish between the two [7, 14]. 
Musubire et al. have described features that are useful for 
distinguishing paradoxical IRIS from potential alternative 
diagnoses [14]. Our patient received cART for more than 
3 years and showed (1) a gradual increase in CD4 T-cell 
counts, reaching almost 200/μL; (2) suppressed plasma 
HIV RNA levels that remained below the detection limit 
for more than 3  years; (3) good cART and FLCZ main-
tenance therapy adherence; and (4) negative brain tis-
sue culture results and very low cryptococcal antigen 
titers in the CSF. These findings indicated cryptococcal 
IRIS rather than reinfection or relapse. Because nonvi-
able yeasts can occasionally linger in the central nerv-
ous system (CNS), positive fungal staining with negative 
fungal cultures in the CNS samples is not considered to 
be enough evidence to diagnose relapse [14]. However, it 
should be taken into consideration that a negative cryp-
tococcal culture is not an absolute requirement for the 
diagnosis of cryptococcal IRIS. For example, spinal fluid 
may be sterile when a patient is treated with ampho-
tericin B or high-dose FLCZ [15]. In addition, crypto-
coccal antigen titers are considered to be unreliable for 
differentiating cryptococcal IRIS from the early phase of 
relapse [14].
It is important to distinguish relapse from late-onset 
cryptococcal IRIS because they require different types of 
treatment. Cryptococcal relapse may require re-induc-
tion antifungal therapy [14], while cryptococcal IRIS may 
require anti-inflammatory drugs, such as nonsteroidal 
anti-inflammatory drugs or corticosteroids [7, 15].
Several retrospective studies have reported the follow-
ing risk factors for developing cryptococcal IRIS: higher 
pre-cART HIV RNA load, lower CD4 cell counts with a 
greater CD4 cell count increase in the first 6 months of 
cART, and a higher organism or antigen burden at base-
line and at cART initiation [8, 10, 11]. Paucities of neu-
trophils, proteins, and cytokines (including TNF-α and 
interleukin-2, 6, 8, and 17) in the CSF have also been sug-
gested to be risk factors for developing cryptococcal IRIS 
[16]. Although the timing of the start of cART following 
cryptococcal meningitis may be a predictor for the devel-
opment of cryptococcal IRIS, the optimal timing of cART 
has yet to be determined and should be individualized 
[10].
Cryptococcal meningitis associated with IRIS is a 
potentially fatal disease with a mortality rate that is 
twice as high as that of cryptococcal meningitis in ART-
naïve HIV-infected patients [17]. Given that increased 
Fig. 2 The pathological examination of the brain biopsy. The pathological examination of the brain biopsy of the left frontal lobe revealed inflam‑
matory cells, such as polymorphonuclear cells (white arrowheads), and many rounded yeast‑like cells (white arrows) in the subarachnoid cavity and 
periarteriolar spaces. Fungal structures compatible with Cryptococcus species were observed on periodic acid‑Schiff (a) and Grocott’s (b) staining 
(magnification ×100)
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intracranial pressure (ICP) (higher than 25  cm H2O) is 
often reported in patients with cryptococcal meningitis 
associated with IRIS, repeated lumbar punctures need 
to be performed to reduce the ICP in two-thirds of the 
cases [18]. Our patient was administered corticosteroids, 
which have sometimes been used previously for patients 
with serious conditions, such as extremely high ICP or 
focal neurologic deficits. Some experts use prednisone 
(0.5–1  mg/kg, daily) or an equivalent, whereas others 
may use a higher dose of dexamethasone that is then 
tapered over 2–6 weeks [19]. Although there is some evi-
dence suggesting the need to discontinue cART in very 
severe cases, there is no need to discontinue cART in 
most non-severe cases [20].
Conclusion
We have reported the case of a patient with AIDS who 
developed symptoms of cryptococcal IRIS 41  months 
after starting cART. Although cryptococcal IRIS usually 
develops within 1  year after starting cART, it can also 
occur much later. To the best of our knowledge, the time 
between cART initiation and the onset of cryptococcal 
IRIS in this patient is the longest that has been reported 
in the literature. It is necessary to carefully distinguish 
cryptococcal IRIS from relapse in such cases; although 
cryptococcal IRIS and relapse may have similar symp-
toms, each requires different treatments.
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